The effect of cholecalciferol for lowering albuminuria in chronic kidney disease: A prospective controlled study

Nephrology Dialysis Transplantation

Volumn 29, Issue 1, 2014, Pages 97-109

  Molina, Pablo ^a,b   Górriz, José L ^a   Molina, Mariola D ^c   Peris, Ana ^d   Beltrán, Sandra ^a   Kanter, Julia ^a   Escudero, Verónica ^a   Romero, Ramón ^b   Pallardó, Luis M ^a,e  

^a HOSPITAL UNIVERSITARIO DR PESET   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c UNIVERSITY OF ALICANTE   (Spain)

^d HOSPITAL FRANCESC DE BORJA   (Spain)

^e UNIVERSITY OF VALENCIA   (Spain)

Author keywords

albuminuria; chronic kidney disease; hyperparathyroidism; vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; ALBUMIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM; CALCIUM ANTAGONIST; COLECALCIFEROL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; PARATHYROID HORMONE; PHOSPHATE;

ADULT; AGED; ALBUMINURIA; ARTICLE; BLOOD PRESSURE; BODY MASS; BODY WEIGHT; CHRONIC KIDNEY DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; MACROALBUMINURIA; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEINURIA; SECONDARY HYPERPARATHYROIDISM; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION;

ALBUMINURIA; CHRONIC KIDNEY DISEASE; HYPERPARATHYROIDISM; VITAMIN D;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ALBUMINURIA; CHOLECALCIFEROL; DIETARY SUPPLEMENTS; DISEASE PROGRESSION; FEMALE; HUMANS; HYPERPARATHYROIDISM; MALE; MIDDLE AGED; PARATHYROID HORMONE; PHOSPHATES; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY, CHRONIC; VITAMIN D; VITAMIN D DEFICIENCY; VITAMINS; YOUNG ADULT;

EID: 84891020938     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gft360     Document Type: Article

References (56)

1. Astor BC, Matsushita K, Gansevoort RT et al. The Chronic Kidney Disease Prognosis Consortium: lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. Kidney Int 2011; 79: 1331-1340
2. Hemmelgarn BR, Manns BJ, Lloyd A et al. Alberta kidney disease network: relation between kidney function, proteinuria, and adverse outcomes. JAMA 2010; 303: 423-429
3. de Zeeuw D, Remuzzi G, Parving HH et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 2004; 65: 2309-2320
4. de Zeeuw D, Remuzzi G, Parving HH et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 2004; 110: 921-927
5. Agarwal R. Vitamin D, proteinuria, diabetic nephropathy, and progression of CKD. Clin J Am Soc Nephrol 2009; 4: 1523-1528
6. Górriz JL, Molina P, Bover J et al. Characteristics of bone mineral metabolism in patients with stage 3-5 chronic kidney disease not on dialysis: results of the OSERCE study. Nefrologia 2013; 33: 46-60
7. Mehrotra R, Hermah D, Budoff M et al. Hypovitaminosis D in chronic kidney disease. Clin J Am Soc Nephrol 2008; 3: 1144-1151
8. Levin A, Bakris GL, Molitch M et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorous in patients with chronic kidney disease. Kidney Int 2007; 71: 31-38
9. LaClair R, Hellman RN, Karp SL et al. Prevalence of calcidiol deficiency in CKD: a cross-sectional study across latitudes in the United States. Am J Kidney Dis 2005; 45: 1026-1033
10. Gonzalez ES, Sachdeva A, Oliver DA et al. Vitamin D insufficiency and deficiency in chronic kidney disease. A single center observational study. Am J Nephrol 2004; 24: 503-510
11. Looker AC, Dawson-Hughes B, Calvo MS et al. Serum 25-hydro-xyvitamin D status of adolescents and adults in two seasonal sub-populations from NHANES III. Bone 2002; 30: 771-777
12. Melamed ML, Astor B, Michos ED et al. 25-Hydroxyvitamin D levels, race, and the progression of kidney disease. J Am Soc Nephrol 2009; 20: 2631-2639
13. De Boer IH, Ioannou GN, Kestenbaum B et al. 25-Hydroxyvita-min D levels and albuminuria in the Third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis 2007; 50: 69-77
14. Holden RM, Morton AR, Garland JS et al. Vitamins K and D status in stages 3 to 5 chronic kidney disease. Clin J Am Soc Nephrol 2010; 5: 590-597
15. Ravani P, Malberti F, Tripepi G et al. Vitamin D levels and patient outcome in chronic kidney disease. Kidney Int 2009; 75: 88-95
16. Mehrotra P, Kermah DA, Salusky IB et al. Chronic kidney disease, hypovitaminosis D, and mortality in the United States. Kidney Int 2009; 76: 977-983
17. Matías PJ, Ferreira C, Jorge C et al. 25-Hydroxyvitamin D3, arterial calcifications and cardiovascular risk markers in haemodialy-sis patients. Nephrol Dial Transplant 2009; 24: 611-618
18. London GM, Guérin AP, Verbeke FH et al. Mineral metabolism and arterial functions in end-stage renal disease. Hypertension 2001; 38: 938-942
19. de Zeeuw D, Agarwal R, Amdahl M et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet 2010; 376: 1543-1551
20. Fishbane S, Chittineni H, Packman M et al. Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial. Am J Kidney Dis 2009; 54: 647-652
21. Alborzi P, Patel NA, Peterson C et al. Paricalcitol reduces albumi-nuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial. Hypertension 2008; 52: 249-255
22. Agarwal R, Acharya M, Tian J et al. Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int 2005; 68: 2823-2828
23. Kim MJ, Frankel AH, Donaldson M et al. Oral cholecalciferol decreases albuminuria and urinary TGF-b1 in patients with type 2 diabetic nephropathy on established renin-angiotensin-aldosterone system inhibition. Kidney Int 2011; 80: 851-860
24. Al-Badr W, Martin KJ. Vitamin D and kidney disease. Clin J Am Soc Nephrol 2008; 3: 1555-1560
25. Alvarez JA, Law J, Coakley KE et al. High-dose cholecalciferol reduces parathyroid hormone in patients with early chronic kidney disease: a pilot, randomized, double-blind, placebo-controlled trial. Am J Clin Nutr 2012; 96: 672-679
26. Marckmann P, Agerskow H, Thineshkumar S et al. Randomized controlled trial of cholecalciferol supplementation in chronic kidney disease patients with hypovitaminosis D. Nephrol Dial Transplant 2012; 27: 3523-3531
27. Moe SM, Saifullah A, LaClair RE et al. A randomized trial of chole-calciferol versus doxercalciferol for lowering parathyroid hormone in chronic kidney disease. Clin J Am Soc Nephrol 2010; 5: 299-306
28. Garcia-Lopes MG, Pillar R, Kamimura RP et al. Cholecalciferol supplementation in chronic kidney disease: restoration of vitamin D status and impact on parathyroid hormone. Ann Nutr Metab 2012; 61: 74-82
29. Kandula P, Dobre M, Schold JD et al. Vitamin D supplementation in chronic kidney disease: a systematic review and meta-analysis of observational studies and randomized controlled trials. Clin J Am Soc Nephrol 2011; 6: 50-62
30. Alvarez J, Wasse H, Tangpricha V. Vitamin D supplementation in pre-dialysis chronic kidney disease: a systematic review. Dermatoendocrinology 2012; 4: 118-127
31. Chandra P, Binongo JN, Ziegler TR et al. Cholecalciferol (vitamin D3) therapy and vitamin D insufficiency in patients with chronic kidney disease: a randomized controlled pilot study. Endocr Pract 2008; 14: 10-17
32. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int 2009; 76(Suppl 113): S1-S130
33. Torregrosa JV, Cannata-Andia J, Bover J et al. SEN Guidelines. Recommendations of the Spanish Society of Nephrology for managing bone-mineral metabolic alterations in chronic renal disease patients. Nefrologia 2008; 28(Suppl 1): S1-S22
34. Levey AS, Coresh J, Greene T et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006; 145: 247-254
35. National Kidney Foundation-Kidney Disease Outcomes and Quality Initiative. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 4(Suppl 3): S1-S201
36. Ross AC, Manson JE, Abrams SA et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the institute of medicine: what clinicians need to know. J Clin Endocri-nol Metab 2011; 96: 53-58
37. Holick MF, Binkley NC, Bischoff-Ferrari HA et al. Evaluation, treatment, and prevention of vitamin D deficiency: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2011; 96: 1911-1930
38. Isakova T, Gutiérrez OM, Patel NM et al. Vitamin D deficiency, inflammation, and albuminuria in chronic kidney disease: complex interactions. J Ren Nutr 2011; 21: 295-302
39. Slinin Y, Ishani A, Rector T. Management of hyperglycemia, dys-lipidemia, and albuminuria in patients with diabetes and CKD: a systematic review for a KDOQI clinical practice guideline. Am J Kidney Dis 2012; 60: 747-769
40. Johnson DJ, Atai E, Chan E et al. KHA-CARI Guideline: early chronic kidney disease: detection, prevention and management. Nephrology 2013; 18: 340-350
41. KDIGO. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 2013; 3: 1-163
42. Levey AS, de Jong PE, Coresh J et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int 2011; 80: 17-28
43. van der Velde M, Matsushita K, Coresh J et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int 2011; 79: 1341-1352
44. Gansevoort RT, Matsushita K, van der Velde M et al. Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts. Kidney Int 2011; 80: 93-104
45. Schmieder RE, Mann JFE, Schumacher H et al. Changes in albu-minuria predict mortality and morbidity in patients with vascular disease. J Am Soc Nephrol 2011; 22: 1353-1364
46. Parving HH, Persson F, Lewis JB et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008; 358: 2433-2446
47. Weir MR. Short-term effects of vitamin D receptor activation on serum creatinine, creatinine generation, and glomerular filtration. Kidney Int 2011; 80: 1016-1017
48. Dogan E, Erkoc R, Sayarlioglu H et al. Effect of depot oral chole-calciferol treatment on secondary hyperparathyroidism in stage 3 and stage 4 chronic kidney diseases patients. Ren Fail 2008; 30: 407-410
49. Oksa A, Spustová V, Krivosíková Z et al. Effects of long-term cholecalciferol supplementation on mineral metabolism and cal-ciotropic hormones in chronic kidney disease. Kidney Blood Press Res 2008; 31: 322-329
50. Lajdova I, Spustova V, Oksa A et al. Intracellular calcium homeo-stasis in patients with early stages of chronic kidney disease: effects of vitamin D3 supplementation. Nephrol Dial Transplant 2009; 24: 3376-3381
51. Taner B, Abdulkadir U. Effect of cholecalciferol on parathyroid hormone and vitamin D levels in chronic kidney disease. Minerva Urol Nefrol 2011; 63: 287-292
52. Hari P, Gupta N, Hari S et al. Vitamin D insufficiency and effect of cholecalciferol in children with chronic kidney disease. Pediatr Nephrol 2010; 25: 2483-2488
53. Palmer SC, McGregor DO, Craig JC et al. Vitamin D compounds for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev 2009; 4: CD008175
54. Coyne D, Acharya M, Qiu P et al. Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD. Am J Kidney Dis 2006; 47: 263-276
55. Shroff R, Wan M, Gullett A et al. Ergocalciferol supplementation in children with CKD delays the onset of secondary hyperparathyroid-ism: a randomized trial. Clin J Am Soc Nephrol 2012; 7: 216-223
56. Rucker D, Tonelli M, Coles MG et al. Vitamin D insufficiency and treatment with oral vitamin D3 in northern-dwelling patients with chronic kidney disease. J Nephrol 2009; 22: 75-82